Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan.

ABSTRACT:

Background

Few studies have investigated treatment options for patients with Alzheimer's disease (AD) showing a poor response to oral cholinesterase inhibitors (ChEIs) in Japan.

Objective

To investigate the efficacy and safety of switching from oral ChEIs to rivastigmine transdermal patch in patients with AD.

Methods

In this multicenter, open-label, phase IV study in outpatient clinics in Japan, patients with mild-moderate AD who had a poor response to or experienced difficulty in continuing donepezil or galantamine were switched to rivastigmine transdermal patch (5 cm²; loaded dose 9 mg, delivery rate 4.6 mg/24 h) with a 1-step titration in week 4 (10 cm²; loaded dose 18 mg, delivery rate 9.5 mg/24 h), which was continued for 4 weeks in the titr

SUBMITTER: Ueda K 

PROVIDER: S-EPMC6751467 | biostudies-literature | 2019 May-Aug

REPOSITORIES: biostudies-literature